UBS Group
KYNB

UBS Group’s Kyntra Bio KYNB Stock Holding History

UBS Group’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59.3K Sell
7,857
-19,734
-72% -$138K ﹤0.01% 7475
2026
Q1 		$187K Buy
27,591
+18,159
+193% +$142K ﹤0.01% 6676
2025
Q4 		$82.8K Buy
9,432
+765
+9% +$7.48K ﹤0.01% 7003
2025
Q3 		$106K Sell
8,667
-1,620
-16% -$15.2K ﹤0.01% 7084
2025
Q2 		$54.5K Buy
10,287
+465
+5% +$3.39K ﹤0.01% 7700
2025
Q1 		$76.1K Buy
9,822
+1,957
+25% +$23.5K ﹤0.01% 7256
2024
Q4 		$104K Buy
7,865
+6,878
+697% +$63.9K ﹤0.01% 6848
2024
Q3 		$9.84K Sell
987
-1,787
-64% -$27K ﹤0.01% 7763
2024
Q2 		$61.9K Sell
2,774
-1,269
-31% -$39.2K ﹤0.01% 6524
2024
Q1 		$238K Buy
4,043
+800
+25% +$34.5K ﹤0.01% 5729
2023
Q4 		$71.8K Buy
3,243
+3,215
+11,482% +$48.5K ﹤0.01% 6364
2023
Q3 		$599 Sell
28
-4,069
-99% -$160K ﹤0.01% 8387
2023
Q2 		$277K Buy
4,097
+3,114
+317% +$1.29M ﹤0.01% 5259
2023
Q1 		$458K Sell
983
-6,835
-87% -$3.62M ﹤0.01% 4760
2022
Q4 		$3.13M Buy
7,818
+6,155
+370% +$2.36M ﹤0.01% 2935
2022
Q3 		$541K Sell
1,663
-1,746
-51% -$562K ﹤0.01% 4268
2022
Q2 		$900K Sell
3,409
-7,314
-68% -$1.87M ﹤0.01% 3822
2022
Q1 		$3.22M Buy
10,723
+976
+10% +$340K ﹤0.01% 2988
2021
Q4 		$3.44M Sell
9,747
-2,488
-20% -$775K ﹤0.01% 3235
2021
Q3 		$3.13M Buy
12,235
+10,793
+748% +$3.82M ﹤0.01% 3168
2021
Q2 		$960K Sell
1,442
-2,195
-60% -$1.26M ﹤0.01% 4215
2021
Q1 		$3.16M Buy
3,637
+3,533
+3,397% +$3.76M ﹤0.01% 3080
2020
Q4 		$96K Buy
104
+12
+13% +$12.6K ﹤0.01% 5709
2020
Q3 		$94K Sell
92
-4,008
-98% -$4.31M ﹤0.01% 5224
2020
Q2 		$4.15M Sell
4,100
-3,296
-45% -$3.06M ﹤0.01% 2194
2020
Q1 		$6.43M Buy
7,396
+911
+14% +$906K ﹤0.01% 1727
2019
Q4 		$6.95M Buy
6,485
+1,254
+24% +$1.28M ﹤0.01% 2271
2019
Q3 		$4.84M Buy
5,231
+2,678
+105% +$2.94M ﹤0.01% 2415
2019
Q2 		$2.88M Sell
2,553
-619
-20% -$678K ﹤0.01% 2819
2019
Q1 		$4.31M Sell
3,172
-2,763
-47% -$3.75M ﹤0.01% 2324
2018
Q4 		$6.87M Buy
5,935
+4,558
+331% +$5.12M ﹤0.01% 1887
2018
Q3 		$2.09M Buy
1,377
+43
+3% +$66.2K ﹤0.01% 3192
2018
Q2 		$2.09M Sell
1,334
-5,504
-80% -$7.18M ﹤0.01% 3125
2018
Q1 		$7.9M Buy
6,838
+6,727
+6,060% +$8.86M ﹤0.01% 1905
2017
Q4 		$132K Sell
111
-1,436
-93% -$1.8M ﹤0.01% 5192
2017
Q3 		$2.08M Buy
1,547
+1,507
+3,768% +$1.59M ﹤0.01% 3098
2017
Q2 		$33K Sell
40
-5
-11% -$3.48K ﹤0.01% 5949
2017
Q1 		$28K Sell
45
-769
-94% -$468K ﹤0.01% 5906
2016
Q4 		$435K Buy
814
+787
+2,915% +$393K ﹤0.01% 4231
2016
Q3 		$14K Sell
27
-2,076
-99% -$978K ﹤0.01% 6553
2016
Q2 		$863K Buy
2,103
+2,026
+2,631% +$928K ﹤0.01% 3505
2016
Q1 		$41K Sell
77
-1,154
-94% -$575K ﹤0.01% 5648
2015
Q4 		$937K Buy
1,231
+960
+354% +$637K ﹤0.01% 3456
2015
Q3 		$148K Buy
271
+66
+32% +$40K ﹤0.01% 4879
2015
Q2 		$121K Buy
205
+144
+236% +$83.7K ﹤0.01% 5251
2015
Q1 		$48K Sell
61
-1
-2% -$775 ﹤0.01% 6084
2014
Q4 		$42K Buy
+62
New +$39.9K ﹤0.01% 6693

Other funds holding KYNB

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

UBS Group's KYNB Position: Q2 2026 in Review

UBS Group reduced its Kyntra Bio (KYNB) stake by 72% in Q2 2026, selling an estimated $138K and leaving 7,857 shares worth $59.3K. The position accounts for ﹤0.01% of the portfolio, ranked #7475.

UBS Group first reported a position in KYNB in Q4 2014 and has held it in 47 quarters since. The position peaked at $7.9M in Q1 2018. 27 funds tracked by Wall St. Rank hold KYNB as of Q2 2026.

  • UBS Group held 7,857 shares of Kyntra Bio worth $59.3K as of Q2 2026.
  • UBS Group sold 19,734 Kyntra Bio shares in Q2 2026, an estimated $138K.
  • Kyntra Bio made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7475 holding.
  • UBS Group first reported a position in Kyntra Bio in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Kyntra Bio position peaked at $7.9M in Q1 2018.
  • 27 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.